News | Cardiovascular Ultrasound | August 04, 2015

ASE Releases Echo Recommendations for Heart Failure Patients with LVADs

Document examines role of echocardiography across all five phases of patient care

LVADs, heart failure patients, echocardiography, ASE, recommendations, guideline

August 4, 2015 — Over the past several years, advanced heart failure patients who have not responded to medical therapy have been given new hope, and are surviving longer with implanted left ventricular assist devices (LVADs). Although echocardiography is recommended for each phase of care for patients with LVADs, there has been limited published data and no formal guidance for the use of echocardiography in this growing patient population. In an effort to fill this gap, a new document, Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography, will appear in the August 2015 issue of the Journal of the American Society of Echocardiography (JASE).

Usage of this emerging technology has increased exponentially since the U.S. Food and Drug Administration (FDA) approved a newer generation of LVADs in 2008 for patients unable to undergo heart transplantation, with more than 30,000 patients having now received long duration LVADs worldwide. 

The writing group for this guideline was chaired by Raymond F. Stainback, M.D., FASE, medical director of noninvasive cardiac imaging at Texas Heart Institute, in Houston. Stainback noted, “The recent growth of hospital and ambulatory LVAD patients and a lack of consensus on the performance of LVAD echoes has placed a strain on patient care facilities. Our goal with this guideline is to alleviate this situation by providing a convenient reference for the entire mechanical circulatory support team, including practical LVAD echo exam protocols and checklists for timing and performance of echo exams.”

The new guideline document covers the role of echocardiography throughout the five distinct phases of patient care related to LVADs – preoperative patient assessment, perioperative imaging, postoperative surveillance, postoperative problem-focused echocardiography, and recovery protocols. Stainback also commented that “because this is an emerging area, the writing group spent a lot of time and effort to come to consensus, and many of our recommendations are based on expert opinions from high-volume LVAD implant centers. LVAD echo exams can be rather straightforward or uniquely time-consuming and complex, depending upon the situation. However, obtaining the correct information expediently, without disrupting normal echo lab operations, has the potential for improving heart failure care and reducing hospital readmissions.”

In conjunction with the publication of the guideline document, Stainback will conduct a live webinar, including a question and answer section, on Aug. 19, 2015 at 1:00 pm ET.

For more information: www.asecho.org


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now